SCHEMBL14917464

SCHEMBL14917464

CCNC(=O)c1cnccc1N

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.46
ALDH1A1 P00352 4/20 0.46
GAA P10253 3/20 0.46
GLA P06280 1/20 0.46
KDM5A P29375 1/20 0.44
TDP1 Q9NUW8 2/20 0.43
KDM6B O15054 2/20 0.43
KDM4C Q9H3R0 2/20 0.43
MEN1 O00255 1/20 0.43
KDM4A O75164 1/20 0.43
MAPT P10636 1/20 0.43
THRB P10828 1/20 0.43
KMT2A Q03164 1/20 0.43
KDM4D Q6B0I6 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
SIRT3 Q9NTG7 1/20 0.42
CA1 P00915 1/20 0.42
CA9 Q16790 1/20 0.42
HPGD P15428 2/20 0.40
PIM1 P11309 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4673791 0.87 KDM4E (0.58) KDM4EALDH1A1GAAGLAKDM5A
SCHEMBL16879250 0.81 TGFBR1 (0.49) KDM4EALDH1A1GAAGLA
SCHEMBL21772099 0.81 TGFBR1 (0.49) KDM4EALDH1A1GAAGLA
SCHEMBL15401922 0.81 NAMPT (0.45) KDM4EALDH1A1GAAGLATDP1
SCHEMBL13162018 0.81 SIRT3 (0.56) GAAKDM5ATDP1KDM6BKDM4C
SCHEMBL30138224 0.81 SIRT3 (0.56) GAAKDM5ATDP1KDM6BKDM4C
Ammonia Solution, Strong SCHEMBL27706531 0.81 GAA (0.50) KDM4EALDH1A1GAAGLAKDM5A
SCHEMBL1232259 0.81 GAA (0.50) KDM4EALDH1A1GAAGLAKDM5A
SCHEMBL12516911 0.80 KDM4C (0.53) KDM4EALDH1A1GAAKDM5ATDP1
SCHEMBL18491204 0.80 L3MBTL1 (0.47) KDM4EALDH1A1GAAGLATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12479830-B2 Homopiperazinyl and homopiperidinyl quinazolin-4(3H)-one derivatives having multimodal activity against pain ESTEVE PHARMACEUTICALS, S.A. (ES) 2025-11-25 US disclosed
US-20220380345-A1 HOMOPIPERAZINYL AND HOMOPIPERIDINYL QUINAZOLIN-4(3H)-ONE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN ESTEVE PHARMACEUTICALS, S.A. (ES) 2022-12-01 US disclosed
US-8895585-B2 Nicotinamide derivative or salt thereof FUJIFILM CORPORATION (JP) 2014-11-25 US disclosed
US-8809371-B2 2014-08-19 US disclosed
US-8772320-B2 2014-07-08 US disclosed
US-20130116430-A1 NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF FUJIFILM CORPORATION (JP) 2013-05-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116430-A1 NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF SYK, CD38, BTK KDM4E 2420/4885ALDH1A1 1638/4885GAA 3096/4885
US-12479830-B2 Homopiperazinyl and homopiperidinyl quinazolin-4(3H)-one derivatives having multimodal activity against pain OPRD1, SIGMAR1, OPRK1 KDM4E 4369/4885ALDH1A1 1777/4885GAA 3858/4885
US-20220380345-A1 HOMOPIPERAZINYL AND HOMOPIPERIDINYL QUINAZOLIN-4(3H)-ONE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN OPRD1, SIGMAR1, OPRK1 KDM4E 4369/4885ALDH1A1 1777/4885GAA 3858/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.